Virax raises $3.25 million
Thursday, 13 January, 2005
Virax (ASX:VHL) has secured $3.25 million of the $4 million it was aiming to raise through a non-renounceable share purchase plan.
The funds will go towards the company's hepatitis B and prostate cancer programs. In late December 2004, Virax announced that a preclinical trial of a preliminary drug developed using its Co-X-Gene technology had induced an immune response against prostate cancer cells.
The company plans to commence animal toxicology work this year, with a view to moving into human trials.
Widespread resistance to common antibiotics is increasing: WHO
Increasing resistance to essential antibiotics poses a growing threat to global health, with one...
Dopamine helps our brains to let go of memories
In a discovery that could reshape how we think about memory, researchers at Flinders University...
Vaccine for elephant herpesvirus found to be safe
The vaccine could prevent deadly elephant endotheliotropic herpesvirus in calves — the...
